NCT00991562 (CLINICAL TRIAL/ IMGN-901/ LORVOTUZUMAB MERTANSINE/ BB-10901)

Study Title
IMGN901 in Combination With Lenalidomide and Dexamethasone (NCT00991562)

Trial Description
The purpose of this study is to test IMGN901 (also known as Lorvotuzumab mertansine or BB-10901) in combination with lenalidomide and dexamethasone every 28 days.

This trial is sponsored by ImmunoGen, Inc [1]

Study Data

  • Condition: Multiple Myeloma
  • Interventions:
    • Drugs used in this trial
  • Phase: I
  • Estimated Enrollment: 50
  • Start: December 2009
  • Completion: October 2014
  • Last verified: November 2014

Study Schematic 

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 10, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.